NEOPLASIA

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADA DEFICIENCY, ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, ANDROGEN INSENSITIVITY, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, {?THYROID CANCER, NONMEDULLARY, 5}, DESMOID DISEASE, HEREDITARY, PORPHYRIA CUTANEA TARDA, PORPHYRIA, HEPATOERYTHROPOIETIC, {PORPHYRIA CUTANEA TARDA, SUSCEPTIBILITY TO}, SMALL CELL CANCER OF THE LUNG, SOMATIC, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, TUBEROUS SCLEROSIS 2, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, ADRENAL CORTICAL CARCINOMA, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, {BUDD-CHIARI SYNDROME}, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, PROTEUS SYNDROME, SOMATIC, TYLOSIS WITH ESOPHAGEAL CANCER, {CELIAC DISEASE, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA

F5, CTNNB1, RUNX1, MYC, POT1, CREBBP, HABP2, IGF2R, CDH1, TP53, CBL, MMP1, IL6, IFNG, CASP8, RHBDF2, APC, AKT1, AR, IL1B, ADA, ERBB2, SERPINA1, NME1, STAT3, HLA-DQA1, HFE, RB1

MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4, EMBERGER SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, IMMUNODEFICIENCY 21, {MELANOMA, CUTANEOUS MALIGNANT, 3}, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 4, PAPILLARY THYROID CARCINOMA, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, OLMSTED SYNDROME, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, IMMUNODEFICIENCY 10, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, TUBEROUS SCLEROSIS 2, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, STIM1, CTNNB1, RB1CC1, STX11, SERPINA1, PTEN, AKT1, MYD88, PTPN11, TJP2, NKX2-1, GATA2, DLC1, KRAS, CCND1, IFNG, PCNA, MYC, FOXO1, CDH1, HRAS, CDK4, CDC73, ERBB2, BDNF, CREBBP, STAT3, BRAF, ACD, TRPV3

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, IMMUNODEFICIENCY 21, PANCREATIC CANCER/MELANOMA SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, LI-FRAUMENI SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA

GATA1, CDKN2A, CCND1, RB1, TP53, ESR1, CREBBP, STAT3, CDH1, SMARCA4, EP300, CTNNB1, GATA2

WERNER SYNDROME, ATAXIA-TELANGIECTASIA, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, DYSKERATOSIS CONGENITA, X-LINKED, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, MULIBREY NANISM, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, ?N SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, ANDROGEN INSENSITIVITY, PROTEUS SYNDROME, SOMATIC

ATM, AR, DKC1, LIG4, PCNA, STAT3, BLM, TRIM37, WRN, POLD1, AKT1, POLA1

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, SMALL CELL CANCER OF THE LUNG, SOMATIC, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BREAST-OVARIAN CANCER, FAMILIAL 1, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, SOTOS SYNDROME 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ANDROGEN INSENSITIVITY, PROTEUS SYNDROME, SOMATIC

SMARCA4, RNF6, AR, RB1, ESR1, SMAD4, BRCA1, EP300, CTNNB1, AKT1, NSD1, KAT5

POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, IMMUNODEFICIENCY 21, SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADA DEFICIENCY, ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIB, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, HYSTRIX-LIKE ICHTHYOSIS WITH DEAFNESS, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, PORPHYRIA CUTANEA TARDA, PORPHYRIA, HEPATOERYTHROPOIETIC, {PORPHYRIA CUTANEA TARDA, SUSCEPTIBILITY TO}, AGAMMAGLOBULINEMIA, X-LINKED 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, BECKWITH-WIEDEMANN SYNDROME, LEPRECHAUNISM, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, ?IMMUNODEFICIENCY 16, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, CURRARINO SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL DOMINANT, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, SCHOPF-SCHULZ-PASSARGE SYNDROME, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, {BUDD-CHIARI SYNDROME}, NOONAN SYNDROME 4, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, COWDEN SYNDROME 7, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, LYMPHOPROLIFERATIVE SYNDROME 2, XERODERMA PIGMENTOSUM, GROUP B, NEUROCUTANEOUS MELANOSIS, SOMATIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, THROMBOCYTOPENIA 5, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, {CELIAC DISEASE, SUSCEPTIBILITY TO}, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

MYC, POT1, F5, FAS, GNAS, IGF2R, BMPR1A, STK10, PPARG, CD82, PRKAR1A, CDH1, CTNNB1, BTK, MMP1, CDKN2A, WT1, IL1B, CASP8, FGFR4, PIK3CA, SOS1, PDGFRB, CREBBP, HLA-DQA1, TGFBR2, PCNA, ERBB2, IL1RN, SMARCA4, RUNX1, FGFR2, RB1CC1, NME1, ERCC3, MYD88, GATA2, FGFR1, PIK3CD, PTCH2, IFNG, CBL, SMARCE1, CCND1, MET, PAX7, KARS, NKX2-1, TGFBR1, EP300, FOXO1, TLR2, TNFRSF4, SH2D1A, BDNF, STAT3, SEC23B, ACD, ACVR1B, GATA1, MEN1, PDGFRL, PTPRJ, TSG101, NRAS, SUFU, SMAD4, OPCML, ETV6, PPM1D, GDNF, VHL, KIF1B, AKT1, KRAS, KAT5, AIP, ASCL1, PARK2, TINF2, MNX1, FASLG, PHOX2B, EPHB2, CDK4, CDKN1C, NF1, FGFR3, PAX3, ADA, AXIN1, KIT, HMMR, RB1, POLA1, EDARADD, SERPINC1, AR, SMARCB1, CHEK2, TLR4, PIK3R2, NTRK1, PTPN11, ATM, PTPN12, GJB2, DKC1, MAP3K1, INSR, WNT10A, DLC1, TP53, BLM, TRIM28, BRAF, IL6, CDKN1B, PHB, STX11, RET, PTEN, HRAS, DCC, HLA-DQB1, CD27, ESR1, ODC1, HFE

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, FRASIER SYNDROME, IMMUNODEFICIENCY 21, ANDROGEN INSENSITIVITY, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PAPILLARY THYROID CARCINOMA, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, DENYS-DRASH SYNDROME, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, PROTEUS SYNDROME, SOMATIC, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, CHOROID PLEXUS PAPILLOMA

GATA1, CTNNB1, MYC, SMAD4, AR, IL6, RBBP8, GATA2, PPARG, STAT3, AKT1, SMARCA4, KAT5, BAX, TP53, WT1, NKX2-1, EP300, MAX, RB1, CREBBP, ESR1, TGFBR2

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, FRASIER SYNDROME, IMMUNODEFICIENCY 21, PANCREATIC CANCER/MELANOMA SYNDROME, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, SOTOS SYNDROME 1, ADRENAL CORTICAL CARCINOMA, ADENOMAS, SALIVARY GLAND PLEOMORPHIC, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, DENYS-DRASH SYNDROME, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, LYNCH SYNDROME I, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, THROMBOCYTOPENIA 5, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, PAPILLARY THYROID CARCINOMA, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

GATA1, AR, SMARCA4, TP53, SUFU, PAX3, CHEK2, ERBB2, ETV6, CDKN2A, GATA2, PPARG, ESR1, PLAG1, NSD1, BRCA1, AKT1, CTNNB1, MSH2, CCND1, ASCL1, HOXB13, RUNX1, PAX7, WT1, NKX2-1, LZTR1, MYC, MEN1, EP300, GDNF, PTEN, RB1, TLR4, CREBBP, STAT3, KAT5, TGFBR2

OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {DEBRISOQUINE SENSITIVITY}, {CODEINE SENSITIVITY}, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, LEPRECHAUNISM, ANDROGEN INSENSITIVITY, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, PAPILLARY THYROID CARCINOMA, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, ADRENAL CORTICAL CARCINOMA, TUBEROUS SCLEROSIS 2, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {GLIOMA SUSCEPTIBILITY 9}, {BUDD-CHIARI SYNDROME}, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, PROTEUS SYNDROME, SOMATIC, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA

AR, PPARG, CTNNB1, MYC, POT1, F5, FAS, PLA2G2A, VHL, INSR, AKT1, TP53, KAT5, IL6, IFNG, PCNA, EP300, FOXO1, ERBB2, CYP2D6, ESR1, BRAF, MT-CO1

PROSTATE CANCER 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, {WILMS TUMOR SUSCEPTIBILITY-5}, IMMUNODEFICIENCY 21, PEUTZ-JEGHERS SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, NIJMEGEN BREAKAGE SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, DESMOID DISEASE, HEREDITARY, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, SOTOS SYNDROME 1, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, AGAMMAGLOBULINEMIA, X-LINKED 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, PALMOPLANTAR HYPERKERATOSIS AND TRUE HERMAPHRODITISM, PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND SEX REVERSAL, BECKWITH-WIEDEMANN SYNDROME, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 4, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, LYNCH SYNDROME I, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, CURRARINO SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, NOONAN SYNDROME 4, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, ADENOMAS, SALIVARY GLAND PLEOMORPHIC, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, IMMUNODEFICIENCY, COMMON VARIABLE, 13, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, ANDROGEN INSENSITIVITY, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, TUMOR PREDISPOSITION SYNDROME, {THYROID CANCER, NONMEDULLARY, 4}, XERODERMA PIGMENTOSUM, GROUP B, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, THROMBOCYTOPENIA 5, XERODERMA PIGMENTOSUM, GROUP D, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

MAD1L1, BRCA2, MYC, POT1, GNAS, BMPR1A, MLH1, RBBP8, SEPT9, PPARG, CDH1, CTNNB1, BTK, IKZF1, STK11, CDKN2A, WT1, CDKN1C, MMP1, SMARCA4, NBN, CDC73, ERCC2, SNAI2, PDGFRB, CREBBP, BAP1, TGFBR2, NF2, ERBB2, KRAS, RUNX1, FGFR2, CASP8, LZTR1, NME1, ERCC3, HOXB13, BUB1B, GATA2, PLAG1, PIK3CD, IFNG, CBL, SMARCE1, CCND1, PAX7, KARS, NKX2-1, MEN1, EP300, RAD51, MAX, TNNT2, RB1, PCNA, STAT3, FOXE1, ACD, GATA1, TSG101, SUFU, SMAD4, ETV6, FOXO1, TJP2, APC, VHL, HRAS, BRCA1, AKT1, RSPO1, KAT5, AIP, ASCL1, PARK2, MNX1, TWIST1, CDK4, IL1B, PTEN, FGFR3, PAX3, TLR2, BARD1, AR, SMARCB1, CHEK2, TLR4, POU6F2, NTRK1, PTPN11, ATM, NSD1, DKC1, SOS1, TP53, MSH2, TRIM28, TINF2, IL6, CDKN1B, PHB, BDNF, RET, LZTS1, ZFHX3, DCC, GDNF, RNASEL, ESR1, TRIM37, DICER1

COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, LYMPHOPROLIFERATIVE SYNDROME 2, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, PROTEUS SYNDROME, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, ADRENAL CORTICAL CARCINOMA, BURKITT LYMPHOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

IL6, AURKA, CDKN1B, VHL, ESR1, CASP8, STAT3, CDH1, MYC, EP300, AKT1, TP53, CD27

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, ANDROGEN INSENSITIVITY, PIEBALDISM, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, PROTEUS SYNDROME, SOMATIC, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, CHOROID PLEXUS PAPILLOMA

SMARCA4, GATA1, CREBBP, SNAI2, GDNF, RB1, PPARG, SMAD4, SUFU, ESR1, MYC, AR, STAT3, FOXO1, AKT1, TP53, ERBB2

OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, 46XY SEX REVERSAL 6, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, NEUROCUTANEOUS MELANOSIS, SOMATIC, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, PIEBALDISM, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1, NOONAN SYNDROME 4, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, PROTEUS SYNDROME, SOMATIC

FASLG, NRAS, PDGFRB, KRAS, SH2D1A, CBL, MAP3K1, KIT, SOS1, AKT1, NTRK1, ERBB2, PTPN11

WERNER SYNDROME, ?N SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}

PCNA, RAD51, POLD1, WRN, POLA1, POLE

NEUROFIBROMATOSIS-NOONAN SYNDROME, XERODERMA PIGMENTOSUM, GROUP B, WERNER SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, ROTHMUND-THOMSON SYNDROME, LI-FRAUMENI SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, NEUROFIBROMATOSIS, TYPE 1, XERODERMA PIGMENTOSUM, GROUP D, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, ?N SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, ADRENAL CORTICAL CARCINOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

ERCC3, ERCC2, TP53, BRIP1, NF1, ATR, RTEL1, PCNA, BLM, WRN, RECQL4, POLA1, POLE

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, TYROSINEMIA, TYPE I, EMBERGER SYNDROME, ATAXIA-TELANGIECTASIA, GLIOMA SUSCEPTIBILITY 1, IMMUNODEFICIENCY 21, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, NEUROFIBROMATOSIS-NOONAN SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, {MELANOMA, CUTANEOUS MALIGNANT, 3}, NEUROFIBROMATOSIS, TYPE 1, LEIOMYOMATOSIS AND RENAL CELL CANCER, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, TUBEROUS SCLEROSIS-1, BANNAYAN-RILEY-RUVALCABA SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, MUIR-TORRE SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CARNEY COMPLEX, TYPE 1, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, IMMUNODEFICIENCY 8, PAPILLARY THYROID CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, PEUTZ-JEGHERS SYNDROME, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, NEUROFIBROMATOSIS, TYPE 2, LYNCH SYNDROME I, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, TUBEROUS SCLEROSIS 2, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, ADRENAL CORTICAL CARCINOMA, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, XERODERMA PIGMENTOSUM, GROUP B, AGAMMAGLOBULINEMIA, X-LINKED 1, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, THROMBOCYTOPENIA 5, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, DIAMOND-BLACKFAN ANEMIA 1, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, ?N SYNDROME, CHOROID PLEXUS PAPILLOMA, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

GATA1, FASLG, TSC2, NF2, TGFBR1, MSH2, CDK4, CTNNB1, AURKA, EPHB2, DLC1, POT1, PTEN, ATR, CHEK2, ETV6, BCL10, PIK3CA, BMPR1A, ATM, ERCC3, CDKN2A, STK10, BUB1B, MYD88, CORO1A, FGFR1, STAT3, MAP3K1, PCNA, ERBB2, PRKAR1A, HRAS, BRCA1, AKT1, BTK, SMARCA4, AXIN1, SOS1, CCND1, ESR1, STK11, AR, CARD11, CDKN1B, PHB, NF1, FH, ACVR1B, BDNF, CDKN3, LIG4, GATA2, EP300, FOXO1, TP53, POLD1, CDH1, SMARCB1, POLE, DCC, IL1B, FAH, RPS19, MYC, HIP1, SMAD4, CREBBP, TSC1, TGFBR2, KAT5, BRAF, TLR2, RB1, POLA1

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, IMMUNODEFICIENCY 24, FRASIER SYNDROME, IMMUNODEFICIENCY 21, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, SOTOS SYNDROME 1, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, PAPILLARY THYROID CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, DENYS-DRASH SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, LYNCH SYNDROME I, ADRENAL CORTICAL CARCINOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, BECKWITH-WIEDEMANN SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

GATA1, BARD1, VHL, KRAS, AURKA, MYC, SMAD4, PTEN, AR, AKT1, IDH1, PHB, CCND1, RBBP8, GATA2, PPARG, PCNA, SUFU, IL6, BRCA1, CTPS1, MXI1, TSG101, MSH2, TRIM28, BAX, RUNX1, TP53, WT1, CASP8, NKX2-1, LZTR1, CHEK2, SMARCA4, EP300, CDH1, MAX, NSD1, SNAI2, ERBB2, BDNF, CREBBP, ESR1, KAT5, CTNNB1, RB1, PAX3

ADRENAL CORTICAL CARCINOMA, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BREAST-OVARIAN CANCER, FAMILIAL 1, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, CHOROID PLEXUS PAPILLOMA, {GLIOBLASTOMA 3}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

SMARCE1, TP53, MYC, CREBBP, EP300, BRCA2, SMARCA4, KAT5

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4, EMBERGER SYNDROME, ATAXIA-TELANGIECTASIA, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, IMMUNODEFICIENCY 21, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, SMALL CELL CANCER OF THE LUNG, SOMATIC, IMMUNODEFICIENCY 24, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, {MELANOMA, CUTANEOUS MALIGNANT, 3}, OLIGODONTIA-COLORECTAL CANCER SYNDROME, PIEBALDISM, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, SOTOS SYNDROME 1, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, PAPILLARY THYROID CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, WERNER SYNDROME, DENYS-DRASH SYNDROME, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, ROTHMUND-THOMSON SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, LYNCH SYNDROME I, ADRENAL CORTICAL CARCINOMA, XERODERMA PIGMENTOSUM, GROUP B, CHOROID PLEXUS PAPILLOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, LI-FRAUMENI SYNDROME, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

GATA1, BARD1, ERBB2, PPARG, TSG101, AXIN2, MYC, DLC1, STX11, EP300, SMAD4, PTEN, CREBBP, AR, WRN, MYD88, GDNF, IDH1, ATM, CTPS1, ERCC3, IL6, BLM, MXI1, BCL10, GATA2, WT1, VHL, ESR1, MAP3K1, NSD1, MEN1, BMPR1A, BRCA1, RECQL4, CTNNB1, AXIN1, TLR4, AIP, MAX, TRIM28, SMARCE1, CCND1, BAX, AURKA, CDKN1B, PHB, CASP8, RUNX1, NKX2-1, KAT5, LZTR1, SUFU, SMARCA4, CDKN2A, TWIST1, TP53, AKT1, HRAS, DCC, WWOX, CDK4, SNAI2, KRAS, CHEK2, NHP2, PCNA, ABCB11, BDNF, RBBP8, STAT3, CDH1, MSH2, ODC1, RB1, PAX3, SMARCB1

PROSTATE CANCER 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, XERODERMA PIGMENTOSUM, GROUP F, IMMUNODEFICIENCY 21, PEUTZ-JEGHERS SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, XERODERMA PIGMENTOSUM, GROUP D, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, PARAGANGLIOMAS 5, NIJMEGEN BREAKAGE SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, DESMOID DISEASE, HEREDITARY, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, BROOKE-SPIEGLER SYNDROME, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, CARCINOID TUMORS, INTESTINAL, AGAMMAGLOBULINEMIA, X-LINKED 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, IMMUNODEFICIENCY 24, BECKWITH-WIEDEMANN SYNDROME, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 4, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, OCCIPITAL HORN SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, ROTHMUND-THOMSON SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, LI-FRAUMENI SYNDROME, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, PARAGANGLIOMAS 1, WITH OR WITHOUT DEAFNESS, NOONAN SYNDROME 4, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, IMMUNODEFICIENCY 14, LEIOMYOMATOSIS AND RENAL CELL CANCER, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, IMMUNODEFICIENCY 8, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, FAMILIAL ADENOMATOUS POLYPOSIS 3, XERODERMA PIGMENTOSUM, GROUP B, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, LYMPHOPROLIFERATIVE SYNDROME 1, COWDEN SYNDROME 7, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, TUBEROUS SCLEROSIS-1, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, TYROSINEMIA, TYPE I, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BLOOM SYNDROME, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D2, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, TUMOR PREDISPOSITION SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, FANCONI ANEMIA, COMPLEMENTATION GROUP T, SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, NEUROCUTANEOUS MELANOSIS, SOMATIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, THROMBOCYTOPENIA 5, DIAMOND-BLACKFAN ANEMIA 1, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, BRCA2, MSH6, MAD1L1, MYC, POT1, FAS, GNAS, MYD88, BMPR1A, STK10, RBBP8, CYLD, PPARG, DKC1, PRKAR1A, IL6, CTPS1, BTK, STK11, CDKN2A, WT1, IL1B, FH, FGFR4, PIK3CA, NBN, POLE, PTPRJ, CDC73, RPS19, ERCC2, PDGFRB, CREBBP, MSH2, BAP1, PTEN, FANCD2, NF2, ERBB2, MLH3, FGFR3, LIG4, RUNX1, TRIM28, RB1CC1, DLC1, LZTR1, NME1, WRN, IDH1, IDH2, ERCC3, HOXB13, BUB1B, IGF2R, GATA2, MLH1, FGFR1, PIK3CD, NTHL1, CBL, SMARCE1, CCND1, MET, PAX7, NKX2-1, MEN1, EP300, RAD51, HIP1, KRAS, TNNT2, RB1, ITK, PCNA, STAT3, FAH, SEC23B, ACD, SEPT9, ACVR1B, GATA1, TGFBR1, VHL, CTNNB1, DDX41, CDKN3, RAD54L, SMAD4, SDHD, ETV6, FOXO1, TJP2, UBE2T, KIF1B, BRCA1, AKT1, SMARCA4, KAT5, AIP, ASCL1, CARD11, PARK2, TP53, BRIP1, PHOX2B, CHEK2, IFNG, POLD1, RECQL4, MCM4, CDKN1C, HAX1, XRCC3, NF1, XRCC4, ABCB11, BRAF, AXIN1, KIT, TLR2, POLA1, ABCC11, NRAS, AR, CORO1A, SMARCB1, AURKA, EPHB2, TLR4, PIK3R2, NTRK1, SDHA, PTPN11, ATM, PTPN12, RRAS2, ATP7A, BCL10, ERCC4, ESR1, MAP3K1, INSR, SOS1, KARS, BLM, FGFR2, TINF2, BAX, CDKN1B, PHB, PMS2, RTEL1, BDNF, RAD54B, RET, APC, HRAS, DCC, FASLG, CDK4, RNASEL, NHP2, TERT, ATR, TSC1, CDH1, CASP8, TGFBR2, TRIM37, MMP1, DICER1, PDGFB

MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, LEPRECHAUNISM, 46XY SEX REVERSAL 6, PIEBALDISM, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, MULTIPLE ENDOCRINE NEOPLASIA IIB, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, PROTEUS SYNDROME, SOMATIC

FGFR4, FGFR2, FGFR1, PDGFRB, PDGFRL, MYC, MET, IGF2R, ERBB2, FGFR3, INSR, EPHB2, STAT3, CDH1, MAP3K1, RET, KIT, AKT1, NTRK1, KRAS, PTPN11

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, ANDROGEN INSENSITIVITY, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, SOTOS SYNDROME 1, ADRENAL CORTICAL CARCINOMA, SMALL CELL CANCER OF THE LUNG, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, TUMOR PREDISPOSITION SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

LIG4, MYC, POT1, AR, NSD1, STAT3, BRCA1, TP53, TRIM28, PIK3CD, CCND1, CDKN1B, PCNA, SMARCA4, EP300, CDC73, RB1, LZTR1, CREBBP, ESR1, BAP1, PTEN

MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, ATAXIA-TELANGIECTASIA, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, BECKWITH-WIEDEMANN SYNDROME, ?N SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, PANCREATIC CANCER/MELANOMA SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, ADRENAL CORTICAL CARCINOMA, SMALL CELL CANCER OF THE LUNG, SOMATIC, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA

BRCA2, PPARG, TSG101, MYC, SMAD4, MYD88, ATM, CDKN2A, VHL, SMARCA4, KAT5, SMARCE1, IL6, TP53, PCNA, TGFBR1, EP300, POLD1, TLR2, CDKN1C, CDC73, KRAS, RB1, CREBBP, ESR1, CTNNB1, POLA1

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, CHOROID PLEXUS PAPILLOMA, GLIOMA SUSCEPTIBILITY 1, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, LEPRECHAUNISM, 46XY SEX REVERSAL 6, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, LI-FRAUMENI SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, SMALL CELL CANCER OF THE LUNG, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, LYMPHOPROLIFERATIVE SYNDROME 1, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, COWDEN SYNDROME 7, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, AGAMMAGLOBULINEMIA, X-LINKED 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, PROTEUS SYNDROME, SOMATIC

RET, PDGFRL, ITK, RUNX1, FGFR4, ERBB2, NTRK1, PTPN11, IGF2R, FGFR1, MAP3K1, INSR, CDH1, AXIN1, FGFR2, CCND1, MET, TP53, TGFBR1, MYC, EPHB2, POLD1, AKT1, HRAS, FASLG, PDGFRB, FGFR3, STAT3, BTK, SEC23B, KIT, MMP1, RB1

MUIR-TORRE SYNDROME, LYNCH SYNDROME I, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, MISMATCH REPAIR CANCER SYNDROME

MLH1, MSH6, MSH2

MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, BANNAYAN-RILEY-RUVALCABA SYNDROME, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, MULTIPLE ENDOCRINE NEOPLASIA IIB, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, TUBEROUS SCLEROSIS 2, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, PROTEUS SYNDROME, SOMATIC, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}

PTPRJ, IL1B, KRAS, IL6, GDNF, PPARG, IFNG, IL1RN, TLR2, MYC, STAT3, RET, EP300, PIK3CA, AKT1, MYD88, PTEN, PTPN11

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, PORPHYRIA CUTANEA TARDA, PORPHYRIA, HEPATOERYTHROPOIETIC, {PORPHYRIA CUTANEA TARDA, SUSCEPTIBILITY TO}, SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADA DEFICIENCY, ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, ANDROGEN INSENSITIVITY, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, {?THYROID CANCER, NONMEDULLARY, 5}, DESMOID DISEASE, HEREDITARY, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, TUBEROUS SCLEROSIS 2, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {GLIOMA SUSCEPTIBILITY 9}, {CELIAC DISEASE, SUSCEPTIBILITY TO}, RUBINSTEIN-TAYBI SYNDROME, {BUDD-CHIARI SYNDROME}, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, CHOROID PLEXUS PAPILLOMA, TYLOSIS WITH ESOPHAGEAL CANCER, LI-FRAUMENI SYNDROME, PROTEUS SYNDROME, SOMATIC

F5, RUNX1, MYC, POT1, CREBBP, HABP2, IGF2R, SERPINA1, CDH1, TP53, CBL, MMP1, IL6, IFNG, PHB, IL1B, RHBDF2, CASP8, TGFBR1, APC, AKT1, AR, TERT, ADA, RB1, SMAD4, NME1, STAT3, HLA-DQA1, HFE, ERBB2

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4, EMBERGER SYNDROME, ATAXIA-TELANGIECTASIA, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, IMMUNODEFICIENCY 21, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, SMALL CELL CANCER OF THE LUNG, SOMATIC, IMMUNODEFICIENCY 24, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, {MELANOMA, CUTANEOUS MALIGNANT, 3}, OLIGODONTIA-COLORECTAL CANCER SYNDROME, PIEBALDISM, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, PROTEUS SYNDROME, SOMATIC, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, PAPILLARY THYROID CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, WERNER SYNDROME, DENYS-DRASH SYNDROME, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, ROTHMUND-THOMSON SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, SOTOS SYNDROME 1, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, LYNCH SYNDROME I, ADRENAL CORTICAL CARCINOMA, XERODERMA PIGMENTOSUM, GROUP B, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, LI-FRAUMENI SYNDROME, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}

GATA1, BARD1, ERBB2, PPARG, CTNNB1, AXIN2, MYC, DLC1, SMARCB1, EP300, SMAD4, PTEN, STX11, CREBBP, AR, BRCA1, ASCL1, WRN, KRAS, MYD88, TWIST1, IDH1, ATM, CTPS1, ERCC3, MXI1, BLM, RBBP8, BCL10, GATA2, WT1, VHL, ESR1, MAP3K1, NSD1, MEN1, BMPR1A, SERPINA1, RECQL4, IL6, TSG101, AXIN1, TLR4, AIP, MAX, TRIM28, FGFR1, SMARCE1, CCND1, BAX, RB1, CDKN1B, PHB, CASP8, RUNX1, NKX2-1, KAT5, LZTR1, SUFU, SMARCA4, CDKN2A, FOXO1, TP53, AKT1, HRAS, DCC, GDNF, CDK4, SNAI2, CHEK2, WWOX, NHP2, PCNA, ABCB11, BDNF, STAT3, CDH1, MSH2, ODC1, TGFBR2, PAX3, AURKA

MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ATAXIA-TELANGIECTASIA, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CARNEY COMPLEX, TYPE 1, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, PAPILLARY THYROID CARCINOMA, TUBEROUS SCLEROSIS 2, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

TSC2, SMARCA4, SMAD4, NME1, PIK3R2, MYD88, GNAS, ATM, RRAS2, CCND1, SEPT9, ESR1, PRKAR1A, CDH1, CDKN1B, TRIM28, ASCL1, BRAF, IL6, PARK2, IFNG, PIK3CA, HRAS, DCC, ERBB2, PAX3, ATR, STAT3, TINF2

ATAXIA-TELANGIECTASIA, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, BLOOM SYNDROME, ?N SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, MISMATCH REPAIR CANCER SYNDROME, LI-FRAUMENI SYNDROME, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, ROTHMUND-THOMSON SYNDROME, LYNCH SYNDROME I, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, ADRENAL CORTICAL CARCINOMA, XERODERMA PIGMENTOSUM, GROUP B, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, RUBINSTEIN-TAYBI SYNDROME, NEUROFIBROMATOSIS, TYPE 1, XERODERMA PIGMENTOSUM, GROUP D, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, CHOROID PLEXUS PAPILLOMA

DDX41, MSH6, SMARCA4, MYC, CREBBP, WRN, ATM, ERCC3, DICER1, RECQL4, BLM, TP53, BRIP1, RAD54B, RTEL1, PCNA, CHEK2, RAD54L, RAD51, POLE, MCM4, ERCC2, NF1, ATR, DKC1, MSH2, POLA1

{SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, DESMOID DISEASE, HEREDITARY, WERNER SYNDROME, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, AGAMMAGLOBULINEMIA, X-LINKED 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, GLIOMA SUSCEPTIBILITY 1, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OLIGODONTIA-COLORECTAL CANCER SYNDROME, BROOKE-SPIEGLER SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PEUTZ-JEGHERS SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, TUBEROUS SCLEROSIS 2, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, NOONAN SYNDROME 4, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, COWDEN SYNDROME 7, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, TUBEROUS SCLEROSIS-1, ?N SYNDROME, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, MUIR-TORRE SYNDROME, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, XERODERMA PIGMENTOSUM, GROUP B, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, DIAMOND-BLACKFAN ANEMIA 1, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

PCNA, GATA1, TSC2, CYLD, BARD1, AR, SMARCA4, AXIN2, EPHB2, DLC1, POT1, ATR, CHEK2, FAS, WRN, BCL10, RAD51, PTPN11, ATM, ERCC3, CARD11, BLM, BUB1B, SEPT9, PPARG, STAT3, MAP3K1, MET, SUFU, ERBB2, PIK3CA, HRAS, BRCA1, PRKAR1A, AKT1, BTK, CTNNB1, AXIN1, SOS1, CCND1, ESR1, CBL, STK11, SEC23B, CDKN2A, PARK2, RB1, CDKN1B, NKX2-1, TLR4, RUNX1, KIT, BDNF, KAT5, LZTR1, RB1CC1, TGFBR1, EP300, FOXO1, TP53, APC, AURKA, SMARCB1, DCC, TINF2, TERT, CDK4, RPS19, MYC, BAX, PDGFRB, PTPRJ, SMAD4, CREBBP, NME1, TSC1, TGFBR2, MSH2, BRAF, ACD, ODC1, PTEN, POLA1

{SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, DESMOID DISEASE, HEREDITARY, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, AGAMMAGLOBULINEMIA, X-LINKED 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, GLIOMA SUSCEPTIBILITY 1, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OLIGODONTIA-COLORECTAL CANCER SYNDROME, BROOKE-SPIEGLER SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PEUTZ-JEGHERS SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, LI-FRAUMENI SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, NOONAN SYNDROME 4, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, COWDEN SYNDROME 7, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, TUBEROUS SCLEROSIS-1, ?N SYNDROME, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PIEBALDISM, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, MUIR-TORRE SYNDROME, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, XERODERMA PIGMENTOSUM, GROUP B, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, DIAMOND-BLACKFAN ANEMIA 1, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, MAD1L1, MYC, POT1, FAS, MLH1, CYLD, PPARG, PRKAR1A, CDK4, BTK, STK11, CDKN2A, PIK3CA, SOS1, ERBB2, CREBBP, BLM, PDGFRB, NF2, SMARCA4, RUNX1, RB1CC1, LZTR1, NME1, WRN, ERCC3, BUB1B, CBL, CCND1, MET, NKX2-1, TGFBR1, EP300, FOXO1, MAX, RB1, BDNF, STAT3, SEC23B, ACD, SEPT9, GATA1, MEN1, CTNNB1, SUFU, SMAD4, RAD51, BRCA1, AKT1, KRAS, AXIN1, CARD11, PARK2, AXIN2, TP53, EPHB2, TERT, RPS19, PTEN, PTPRJ, BRAF, KAT5, KIT, POLA1, BARD1, AR, SMARCB1, AURKA, CHEK2, TLR4, BCL10, PTPN11, ATM, ESR1, MAP3K1, DLC1, MSH2, TINF2, BAX, CDKN1B, PCNA, APC, HRAS, DCC, FASLG, ATR, TSC1, TGFBR2, ODC1

{VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, ADRENAL CORTICAL CARCINOMA, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, PROTEUS SYNDROME, SOMATIC, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, LI-FRAUMENI SYNDROME, CHOROID PLEXUS PAPILLOMA

SMARCA4, FASLG, FOXO1, TERT, CCND1, MET, ERBB2, KRAS, TP53, CTNNB1, MYC, CDKN1B, STAT3, CDH1, PTPN11, TGFBR1, FAS, SOS1, AKT1, TGFBR2, HRAS

OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, PANCREATIC CANCER/MELANOMA SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, LI-FRAUMENI SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, NEUROFIBROMATOSIS, TYPE 2, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, TUBEROUS SCLEROSIS 2, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, XERODERMA PIGMENTOSUM, GROUP D, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, NF2, CTNNB1, TP53, MYC, SMAD4, FAS, AKT1, PIK3CA, PTPN11, SMARCA4, KRAS, CCND1, CDH1, KARS, AXIN1, SOS1, CDKN2A, MET, CDKN1B, FASLG, TGFBR1, FOXO1, PTEN, HRAS, TERT, ERCC2, ERBB2, POT1, CREBBP, STAT3, TGFBR2

WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, IMMUNODEFICIENCY 21, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIB, DESMOID DISEASE, HEREDITARY, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, AGAMMAGLOBULINEMIA, X-LINKED 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OLIGODONTIA-COLORECTAL CANCER SYNDROME, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PEUTZ-JEGHERS SYNDROME, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 4, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, SCHOPF-SCHULZ-PASSARGE SYNDROME, LI-FRAUMENI SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, NOONAN SYNDROME 4, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, IMMUNODEFICIENCY 14, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, IMMUNODEFICIENCY 8, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, LYMPHOPROLIFERATIVE SYNDROME 1, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CARNEY COMPLEX, TYPE 1, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, XERODERMA PIGMENTOSUM, GROUP B, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, THROMBOCYTOPENIA 5, XERODERMA PIGMENTOSUM, GROUP D, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

MYC, POT1, FAS, GNAS, MYD88, HAX1, PRKAR1A, CDK4, TSG101, BTK, STK11, CDKN2A, WT1, TERT, PIK3CA, SOS1, SNAI2, ERCC2, PDGFRB, CREBBP, ERBB2, KRAS, RUNX1, CASP8, LZTR1, AR, WRN, ERCC3, BAX, GDNF, GATA2, PIK3CD, CBL, SMARCE1, CCND1, MET, PAX7, TGFBR1, EP300, RAD51, MAX, RB1, ITK, PCNA, STAT3, ACD, SEPT9, GATA1, CTNNB1, SMAD4, ETV6, FOXO1, TJP2, BRCA1, AKT1, SMARCA4, AXIN1, AIP, ASCL1, CARD11, PARK2, AXIN2, TP53, TWIST1, CDH1, IL1B, PTEN, PTPRJ, PAX3, KIT, TLR2, POLA1, SMARCB1, AURKA, CHEK2, TLR4, PIK3R2, BCL10, PTPN11, ATM, PTPN12, DICER1, MAP3K1, INSR, WNT10A, DLC1, MSH2, TRIM28, IL6, CDKN1B, BDNF, RET, APC, HRAS, DCC, FASLG, ATR, ESR1, TGFBR2, TINF2, CORO1A

PROSTATE CANCER 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, XERODERMA PIGMENTOSUM, GROUP F, IMMUNODEFICIENCY 21, PEUTZ-JEGHERS SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, XERODERMA PIGMENTOSUM, GROUP D, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, NIJMEGEN BREAKAGE SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, DESMOID DISEASE, HEREDITARY, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, BROOKE-SPIEGLER SYNDROME, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, AGAMMAGLOBULINEMIA, X-LINKED 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, IMMUNODEFICIENCY 24, BECKWITH-WIEDEMANN SYNDROME, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, OCCIPITAL HORN SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, ROTHMUND-THOMSON SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, LI-FRAUMENI SYNDROME, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, NOONAN SYNDROME 4, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, IMMUNODEFICIENCY 14, LEIOMYOMATOSIS AND RENAL CELL CANCER, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, IMMUNODEFICIENCY 8, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, FAMILIAL ADENOMATOUS POLYPOSIS 3, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, LYMPHOPROLIFERATIVE SYNDROME 1, COWDEN SYNDROME 7, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, TUBEROUS SCLEROSIS-1, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, TYROSINEMIA, TYPE I, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BLOOM SYNDROME, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D2, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, TUMOR PREDISPOSITION SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, FANCONI ANEMIA, COMPLEMENTATION GROUP T, XERODERMA PIGMENTOSUM, GROUP B, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, NEUROCUTANEOUS MELANOSIS, SOMATIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, THROMBOCYTOPENIA 5, DIAMOND-BLACKFAN ANEMIA 1, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, BRCA2, MSH6, MAD1L1, MYC, POT1, FAS, GNAS, MYD88, BMPR1A, STK10, RBBP8, CYLD, PPARG, DKC1, PRKAR1A, IL6, CTPS1, BTK, STK11, CDKN2A, WT1, IL1B, FH, FGFR4, PIK3CA, NBN, POLE, CDC73, RPS19, ERCC2, PDGFRB, CREBBP, MSH2, BAP1, PTEN, FANCD2, NF2, ERBB2, MLH3, PTPRJ, LIG4, RUNX1, TRIM28, CASP8, DLC1, LZTR1, NME1, WRN, ERCC3, HOXB13, BUB1B, GATA2, MLH1, FGFR1, PIK3CD, NTHL1, CBL, CCND1, MET, PAX7, NKX2-1, MEN1, EP300, RAD51, HIP1, KRAS, TNNT2, RB1, ITK, PCNA, STAT3, FAH, SEC23B, ACD, SEPT9, ACVR1B, GATA1, TGFBR1, VHL, CTNNB1, DDX41, CDKN3, RAD54L, SMAD4, ETV6, FOXO1, UBE2T, KIF1B, BRCA1, AKT1, SMARCA4, KAT5, AIP, ASCL1, CARD11, PARK2, TP53, BRIP1, PHOX2B, CHEK2, IFNG, POLD1, RECQL4, MCM4, CDKN1C, HAX1, XRCC3, NF1, FGFR3, ABCB11, BRAF, AXIN1, KIT, TLR2, POLA1, ABCC11, NRAS, AR, CORO1A, SMARCB1, AURKA, EPHB2, TLR4, PIK3R2, NTRK1, PTPN11, ATM, PTPN12, RRAS2, ATP7A, BCL10, ERCC4, ESR1, MAP3K1, INSR, SOS1, KARS, BLM, FGFR2, TINF2, BAX, CDKN1B, PHB, PMS2, RTEL1, BDNF, RAD54B, RET, APC, HRAS, DCC, FASLG, CDK4, RNASEL, NHP2, TERT, ATR, TSC1, CDH1, TGFBR2, TRIM37, MMP1, DICER1, PDGFB

PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, ANDROGEN INSENSITIVITY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, NEUROFIBROMATOSIS-NOONAN SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, ADRENAL CORTICAL CARCINOMA, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, TUBEROUS SCLEROSIS 2, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, RUBINSTEIN-TAYBI SYNDROME, NEUROFIBROMATOSIS, TYPE 1, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, CHOROID PLEXUS PAPILLOMA

NF1, TERT, FGFR2, SMARCA4, IL6, PPARG, IFNG, FGFR1, ESR1, CREBBP, BDNF, STAT3, AR, EP300, FOXO1, TP53, CDKN1B

{MELANOMA, CUTANEOUS MALIGNANT, 3}, BECKWITH-WIEDEMANN SYNDROME, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, LI-FRAUMENI SYNDROME, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, BREAST-OVARIAN CANCER, FAMILIAL 1, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CARNEY COMPLEX, TYPE 1, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, PANCREATIC CANCER/MELANOMA SYNDROME, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC

CDKN1C, CDKN2A, CDKN1B, SMAD4, PRKAR1A, BRCA1, CDK4, HRAS

EMBERGER SYNDROME, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, IMMUNODEFICIENCY 21, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, LEPRECHAUNISM, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 4, ALAGILLE SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, NEUROFIBROMATOSIS, TYPE 2, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, IMMUNODEFICIENCY 10, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, ADRENAL CORTICAL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA

STIM1, RET, CTNNB1, AURKA, CBL, MYC, NF2, PTPN11, TJP2, IL6, GATA2, INSR, CDH1, IFNG, FGFR2, ASCL1, CCND1, TP53, PTPN12, PCNA, MEN1, JAG1, PTPRJ, STAT3, PDGFB, COL7A1

?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PEUTZ-JEGHERS SYNDROME, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, IMMUNODEFICIENCY 14, BANNAYAN-RILEY-RUVALCABA SYNDROME, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

CCND1, CBL, STK11, PIK3CD, IL6, ERBB2, RUNX1, PCNA, MYC, STAT3, PTEN, CREBBP, TINF2, POT1, AKT1, PIK3CA

GLIOMA SUSCEPTIBILITY 1, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, 46XY SEX REVERSAL 6, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, PIEBALDISM, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, ADRENAL CORTICAL CARCINOMA, CHOROID PLEXUS PAPILLOMA, NEUROCUTANEOUS MELANOSIS, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

NRAS, NF2, ERBB2, KRAS, AURKA, CBL, RB1CC1, PAX3, PTEN, NTRK1, PTPN11, FGFR1, ESR1, MAP3K1, BRCA1, AKT1, FGFR2, PARK2, TP53, TLR4, MEN1, PIK3CA, SOS1, HRAS, FASLG, PDGFRB, POT1, CREBBP, STAT3, KIT, SH2D1A

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, IMMUNODEFICIENCY 21, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, SOTOS SYNDROME 1, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, FRASIER SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, PANCREATIC CANCER/MELANOMA SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, {MELANOMA, CUTANEOUS MALIGNANT, 3}, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULTIPLE ENDOCRINE NEOPLASIA IIB, MUIR-TORRE SYNDROME, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, DYSKERATOSIS CONGENITA, X-LINKED, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, PAPILLARY THYROID CARCINOMA, ADENOMAS, SALIVARY GLAND PLEOMORPHIC, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, TUMOR PREDISPOSITION SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, LYNCH SYNDROME I, ADRENAL CORTICAL CARCINOMA, TUBEROUS SCLEROSIS 2, AGAMMAGLOBULINEMIA, X-LINKED 1, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {GLIOMA SUSCEPTIBILITY 9}, ATAXIA-TELANGIECTASIA, THROMBOCYTOPENIA 5, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, LI-FRAUMENI SYNDROME, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

PCNA, GATA1, MAD1L1, RET, PAX7, DKC1, TSG101, TP53, MYC, EP300, SMAD4, PTEN, AR, ASCL1, ETV6, POT1, TWIST1, ATM, SMARCB1, TERT, BUB1B, GATA2, PPARG, ESR1, PLAG1, NSD1, CDKN1B, SUFU, IL6, BRCA1, BAP1, AKT1, BTK, MMP1, SMARCA4, MSH2, WT1, MAX, FGFR2, SMARCE1, CCND1, CDKN2A, RUNX1, KARS, PHB, IL1B, PHOX2B, BDNF, KAT5, LZTR1, CHEK2, MEN1, TLR4, FOXO1, NME1, POLD1, CDH1, ZFHX3, DCC, GDNF, CDKN1C, CDK4, CDC73, SNAI2, TGFBR2, IFNG, RB1, NKX2-1, CREBBP, HOXB13, STAT3, CASP8, AXIN1, TINF2, CTNNB1, ERBB2, PAX3

PROSTATE CANCER 1, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, OCCIPITAL HORN SYNDROME, ROTHMUND-THOMSON SYNDROME, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, TUBEROUS SCLEROSIS 2, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, NOONAN SYNDROME 4, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, ADRENAL CORTICAL CARCINOMA, FAMILIAL ADENOMATOUS POLYPOSIS 3, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, PLEUROPULMONARY BLASTOMA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, ANDROGEN INSENSITIVITY, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, XERODERMA PIGMENTOSUM, GROUP B, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, XERODERMA PIGMENTOSUM, GROUP D, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, BRCA2, MSH6, MYC, GNAS, MYD88, MLH1, HAX1, PRKAR1A, RECQL4, SOS1, PIK3CA, POLE, ERCC2, PDGFRB, CREBBP, MSH2, PTEN, ERBB2, MLH3, NME1, WRN, ERCC3, BUB1B, ABCC11, CBL, CCND1, MET, NTHL1, RAD54L, RAD51, KRAS, IFNG, STAT3, BRAF, SEPT9, TGFBR1, CTNNB1, SMAD4, KIF1B, AKT1, SMARCA4, AXIN1, ASCL1, PARK2, TP53, BRIP1, RAD54B, CDH1, MCM4, XRCC3, NF1, ABCB11, TNNT2, POLA1, DDX41, AR, KLF6, AURKA, CHEK2, TLR4, PIK3R2, ATM, RRAS2, ATP7A, DICER1, DKC1, INSR, DLC1, BLM, TRIM28, TRIM37, IL6, CDKN1B, PHB, PMS2, RTEL1, PCNA, HRAS, DCC, CDK4, RNASEL, NHP2, ATR, ESR1, TINF2

COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, LI-FRAUMENI SYNDROME, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, ANDROGEN INSENSITIVITY, RUBINSTEIN-TAYBI SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, ADRENAL CORTICAL CARCINOMA, CHOROID PLEXUS PAPILLOMA

TP53, CREBBP, SMAD4, AR, EP300, KAT5

PROSTATE CANCER 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, XERODERMA PIGMENTOSUM, GROUP F, IMMUNODEFICIENCY 21, PEUTZ-JEGHERS SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, XERODERMA PIGMENTOSUM, GROUP D, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, {?THYROID CANCER, NONMEDULLARY, 5}, NIJMEGEN BREAKAGE SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, DESMOID DISEASE, HEREDITARY, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, BROOKE-SPIEGLER SYNDROME, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, HYSTRIX-LIKE ICHTHYOSIS WITH DEAFNESS, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, AGAMMAGLOBULINEMIA, X-LINKED 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, PALMOPLANTAR HYPERKERATOSIS AND TRUE HERMAPHRODITISM, PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND SEX REVERSAL, IMMUNODEFICIENCY 24, BECKWITH-WIEDEMANN SYNDROME, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADA DEFICIENCY, ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, OCCIPITAL HORN SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, ROTHMUND-THOMSON SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, LI-FRAUMENI SYNDROME, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, {BUDD-CHIARI SYNDROME}, NOONAN SYNDROME 4, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, IMMUNODEFICIENCY 14, LEIOMYOMATOSIS AND RENAL CELL CANCER, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, BIRT-HOGG-DUBE SYNDROME, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ALAGILLE SYNDROME, IMMUNODEFICIENCY 8, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, FAMILIAL ADENOMATOUS POLYPOSIS 3, IMMUNODEFICIENCY DUE TO PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, LYMPHOPROLIFERATIVE SYNDROME 1, COWDEN SYNDROME 7, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, ADRENAL CORTICAL CARCINOMA, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, TUBEROUS SCLEROSIS-1, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, TYROSINEMIA, TYPE I, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BLOOM SYNDROME, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D2, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, TUMOR PREDISPOSITION SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, FANCONI ANEMIA, COMPLEMENTATION GROUP T, XERODERMA PIGMENTOSUM, GROUP B, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, NEUROCUTANEOUS MELANOSIS, SOMATIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, EXOSTOSES, MULTIPLE, TYPE 2, THROMBOCYTOPENIA 5, DIAMOND-BLACKFAN ANEMIA 1, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, BRCA2, MSH6, MAD1L1, MYC, POT1, F5, FAS, GNAS, MYD88, BMPR1A, STK10, RBBP8, CYLD, PPARG, DKC1, PRKAR1A, IL6, CTPS1, BTK, STK11, CDKN2A, WT1, IL1B, FH, TGFBR1, FGFR4, SMARCA4, PIK3CA, NBN, POLE, DDX41, PTPRJ, CDC73, JAG1, TGFBR2, ERBB2, CREBBP, MSH2, WWOX, BAP1, PTEN, FANCD2, NF2, MLH3, FGFR3, LIG4, RUNX1, TRIM28, RB1CC1, DLC1, LZTR1, NME1, WRN, ERCC3, HOXB13, BUB1B, IGF2R, GATA2, MLH1, FGFR1, ERCC2, PIK3CD, NTHL1, ESR1, CBL, CCND1, MET, PAX7, NKX2-1, FLCN, MEN1, EP300, RAD51, TLR2, HIP1, KRAS, TNNT2, RB1, ITK, PCNA, STAT3, FAH, SEC23B, ACD, SEPT9, ACVR1B, GATA1, GPC3, VHL, CTNNB1, SERPINC1, CDKN3, RAD54L, SMAD4, ETV6, FOXO1, PDGFRB, PNP, UBE2T, KIF1B, BRCA1, AKT1, RSPO1, KAT5, AIP, ASCL1, CARD11, PARK2, TINF2, TP53, BRIP1, PHOX2B, EPHB2, GJB2, IFNG, POLD1, CDH1, MCM4, CDKN1C, HAX1, XRCC3, NF1, IL1RN, PAX3, ABCB11, BRAF, AXIN1, KIT, HMMR, POLA1, ABCC11, NRAS, BARD1, AR, CORO1A, SMARCB1, AURKA, CHEK2, TLR4, HABP2, PIK3R2, NTRK1, PTPN11, ATM, PTPN12, RRAS2, ATP7A, BCL10, ERCC4, TSC1, MAP3K1, INSR, RECQL4, SERPINA1, SOS1, KARS, BLM, FGFR2, ODC1, BAX, CDKN1B, PHB, PMS2, RTEL1, BDNF, RAD54B, RET, APC, HRAS, DCC, GDNF, FASLG, CDK4, RPS19, RNASEL, ADA, NHP2, TERT, ATR, EXT2, CASP8, COL7A1, TRIM37, MMP1, DICER1, PDGFB

PROSTATE CANCER 1, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, OCCIPITAL HORN SYNDROME, ROTHMUND-THOMSON SYNDROME, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, TUBEROUS SCLEROSIS 2, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, NOONAN SYNDROME 4, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, ADRENAL CORTICAL CARCINOMA, FAMILIAL ADENOMATOUS POLYPOSIS 3, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, PLEUROPULMONARY BLASTOMA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, ANDROGEN INSENSITIVITY, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, XERODERMA PIGMENTOSUM, GROUP B, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, XERODERMA PIGMENTOSUM, GROUP D, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, BRCA2, MSH6, MYC, GNAS, MYD88, MLH1, HAX1, PRKAR1A, RECQL4, SOS1, PIK3CA, POLE, ERCC2, PDGFRB, CREBBP, MSH2, PTEN, ERBB2, MLH3, NME1, WRN, ERCC3, BUB1B, ABCC11, CBL, CCND1, MET, NTHL1, RAD54L, RAD51, KRAS, IFNG, STAT3, BRAF, SEPT9, TGFBR1, CTNNB1, SMAD4, KIF1B, AKT1, SMARCA4, AXIN1, ASCL1, PARK2, TP53, BRIP1, RAD54B, CDH1, MCM4, XRCC3, NF1, ABCB11, TNNT2, POLA1, DDX41, AR, KLF6, AURKA, CHEK2, TLR4, PIK3R2, ATM, RRAS2, ATP7A, DICER1, DKC1, INSR, DLC1, BLM, TRIM28, TRIM37, IL6, CDKN1B, PHB, PMS2, RTEL1, PCNA, HRAS, DCC, CDK4, RNASEL, NHP2, ATR, ESR1, TINF2

NEUROFIBROMATOSIS-NOONAN SYNDROME, XERODERMA PIGMENTOSUM, GROUP B, WERNER SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, ROTHMUND-THOMSON SYNDROME, LI-FRAUMENI SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, NEUROFIBROMATOSIS, TYPE 1, XERODERMA PIGMENTOSUM, GROUP D, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, ?N SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, ADRENAL CORTICAL CARCINOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

ERCC3, ERCC2, TP53, BRIP1, NF1, ATR, RTEL1, PCNA, BLM, WRN, RECQL4, POLA1, POLE

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, IMMUNODEFICIENCY 21, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PANCREATIC CANCER/MELANOMA SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, PIEBALDISM, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, ATAXIA-TELANGIECTASIA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, NIJMEGEN BREAKAGE SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, SOTOS SYNDROME 1, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, LYNCH SYNDROME I, ADENOMAS, SALIVARY GLAND PLEOMORPHIC, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, PAPILLARY THYROID CARCINOMA, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, PEUTZ-JEGHERS SYNDROME, BREAST-OVARIAN CANCER, FAMILIAL 1, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, TUMOR PREDISPOSITION SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, {THYROID CANCER, NONMEDULLARY, 4}, ADRENAL CORTICAL CARCINOMA, AGAMMAGLOBULINEMIA, X-LINKED 1, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, THROMBOCYTOPENIA 5, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

PCNA, GATA1, RET, PAX7, TSG101, TP53, MYC, SMAD4, PTEN, AR, ASCL1, ETV6, TWIST1, BMPR1A, ATM, SMARCB1, HOXB13, BUB1B, GATA2, WT1, PPARG, ESR1, PLAG1, NSD1, HRAS, BRCA1, BAP1, AKT1, BTK, MMP1, SMARCA4, MSH2, AIP, TRIM28, STK11, CCND1, CDKN2A, IL6, CDKN1B, PHB, IL1B, TLR4, RUNX1, GNAS, NKX2-1, KAT5, LZTR1, SUFU, MEN1, EP300, FOXO1, NBN, CDH1, ZFHX3, MAX, GDNF, CDKN1C, CDK4, SNAI2, CHEK2, ERBB2, BDNF, CREBBP, STAT3, TGFBR2, FOXE1, PTPN11, CTNNB1, RB1, PAX3

POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, 46XY SEX REVERSAL 6, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, PAPILLARY THYROID CARCINOMA, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, AGAMMAGLOBULINEMIA, X-LINKED 1, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

BRAF, STK10, TGFBR2, CTNNB1, MAP3K1, BTK, PTEN, BMPR1A, TGFBR1, HRAS, TLR2, AKT1, TP53, ACVR1B

XERODERMA PIGMENTOSUM, GROUP B, WERNER SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, ROTHMUND-THOMSON SYNDROME, LI-FRAUMENI SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BLOOM SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, ADRENAL CORTICAL CARCINOMA, CHOROID PLEXUS PAPILLOMA

WRN, RECQL4, ERCC3, TP53, BLM

PROSTATE CANCER 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, IMMUNODEFICIENCY 21, SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADA DEFICIENCY, ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, DIAMOND-BLACKFAN ANEMIA 13, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, DESMOID DISEASE, HEREDITARY, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, SOTOS SYNDROME 1, BROOKE-SPIEGLER SYNDROME, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, CARCINOID TUMORS, INTESTINAL, AGAMMAGLOBULINEMIA, X-LINKED 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, ADENOMAS, MULTIPLE COLORECTAL, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, PALMOPLANTAR HYPERKERATOSIS AND TRUE HERMAPHRODITISM, PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND SEX REVERSAL, BECKWITH-WIEDEMANN SYNDROME, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OLIGODONTIA-COLORECTAL CANCER SYNDROME, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, OCCIPITAL HORN SYNDROME, DENYS-DRASH SYNDROME, ROTHMUND-THOMSON SYNDROME, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL DOMINANT, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4, NOONAN SYNDROME 4, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ALAGILLE SYNDROME, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, XERODERMA PIGMENTOSUM, GROUP B, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, PEUTZ-JEGHERS SYNDROME, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, ADRENAL CORTICAL CARCINOMA, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ?N SYNDROME, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, PARAGANGLIOMAS 1, WITH OR WITHOUT DEAFNESS, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BLOOM SYNDROME, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, COWDEN SYNDROME 7, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, TUMOR PREDISPOSITION SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, FANCONI ANEMIA, COMPLEMENTATION GROUP T, SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, THROMBOCYTOPENIA 5, XERODERMA PIGMENTOSUM, GROUP D, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

MAD1L1, MSH6, MYC, POT1, MYD88, MLH1, RBBP8, CYLD, PPARG, CDH1, CTNNB1, BTK, STK11, CDKN2A, WT1, IL1B, CASP8, MMP1, SMARCA4, PIK3CA, SOS1, CDC73, ERCC2, SNAI2, PDGFRB, SMAD4, CREBBP, MSH2, BAP1, PTEN, PCNA, NF2, ERBB2, MLH3, XRCC4, LIG4, RUNX1, RB1CC1, LZTR1, NME1, WRN, ERCC3, IL6, BUB1B, GATA2, FGFR1, PIK3CD, RPS29, EDARADD, CBL, SMARCE1, CCND1, PAX7, MEN1, EP300, RAD51, MAX, TNNT2, RB1, BDNF, STAT3, SEC23B, ACD, ACVR1B, GATA1, TGFBR1, VHL, TSG101, MUTYH, SDHD, ETV6, FOXO1, UBE2T, HRAS, BRCA1, AKT1, RSPO1, KAT5, ASCL1, CARD11, PARK2, AXIN2, TP53, RAD54B, EPHB2, IFNG, RECQL4, MCM4, TINF2, CDKN1C, NF1, IL1RN, TLR4, ABCB11, AXIN1, TLR2, POLA1, DDX41, BARD1, AR, SMARCB1, AURKA, CHEK2, PAX3, NTRK1, JAG1, PTPN11, ATM, PTPN12, ATP7A, MXI1, NSD1, DKC1, MAP3K1, INSR, SERPINA1, POLE, BLM, TRIM28, BRAF, BAX, CDKN1B, PHB, RNF6, STX11, APC, ZFHX3, DCC, GDNF, CDK4, RNASEL, ADA, ESR1, TGFBR2, TRIM37, DICER1

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, ATAXIA-TELANGIECTASIA, CHOROID PLEXUS PAPILLOMA, GLIOMA SUSCEPTIBILITY 1, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PANCREATIC CANCER/MELANOMA SYNDROME, MULIBREY NANISM, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, ?IMMUNODEFICIENCY 16, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, RUBINSTEIN-TAYBI SYNDROME, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, LYMPHOPROLIFERATIVE SYNDROME 2, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, ADRENAL CORTICAL CARCINOMA, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, AGAMMAGLOBULINEMIA, X-LINKED 1, TUBEROUS SCLEROSIS 2, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

FASLG, ERBB2, KRAS, AURKA, FGFR2, MYC, POT1, PTEN, FAS, MYD88, BMPR1A, ATM, BAX, NTRK1, HAX1, PPARG, ESR1, PTPN11, PIK3CD, CDH1, IFNG, BTK, RUNX1, CBL, CCND1, CDKN2A, IL6, CDKN1B, IL1B, TLR4, PCNA, SERPINA1, BCL10, CASP8, TGFBR1, EP300, PIK3CA, TP53, AKT1, HRAS, TNFRSF4, CD27, SMAD4, IL1RN, BDNF, CREBBP, STAT3, TGFBR2, TRIM37, PDGFRB

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, EMBERGER SYNDROME, ATAXIA-TELANGIECTASIA, GLIOMA SUSCEPTIBILITY 1, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, BECKWITH-WIEDEMANN SYNDROME, IMMUNODEFICIENCY 21, PANCREATIC CANCER/MELANOMA SYNDROME, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ANDROGEN INSENSITIVITY, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, {MELANOMA, CUTANEOUS MALIGNANT, 3}, ?IMMUNODEFICIENCY 16, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, ADRENAL CORTICAL CARCINOMA, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, LYMPHOPROLIFERATIVE SYNDROME 2, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, TUBEROUS SCLEROSIS 2, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

GATA1, FASLG, PAX7, TP53, MYC, SMAD4, PTEN, AR, FAS, PIK3CA, BMPR1A, ATM, CCND1, HAX1, PPARG, ESR1, PTPN11, SERPINA1, TNFRSF4, CDH1, IFNG, TLR4, RUNX1, SMARCE1, CDKN2A, IL6, CDKN1B, IL1B, CASP8, BDNF, PAX3, TGFBR1, GATA2, EP300, FOXO1, AKT1, CDKN1C, CDK4, CD27, ERBB2, PCNA, CREBBP, STAT3, TGFBR2, ACVR1B

ATAXIA-TELANGIECTASIA, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BECKWITH-WIEDEMANN SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, LEPRECHAUNISM, PANCREATIC CANCER/MELANOMA SYNDROME, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, LI-FRAUMENI SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CARNEY COMPLEX, TYPE 1, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, BREAST-OVARIAN CANCER, FAMILIAL 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, AGAMMAGLOBULINEMIA, X-LINKED 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

ATM, FASLG, CDKN1C, CDK4, CDKN2A, PDGFRB, STAT3, CREBBP, BTK, ESR1, PRKAR1A, SMAD4, BRCA1, SOS1, AKT1, CDKN1B, HRAS, INSR

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, ATAXIA-TELANGIECTASIA, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, IMMUNODEFICIENCY 21, PANCREATIC CANCER/MELANOMA SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, {MELANOMA, CUTANEOUS MALIGNANT, 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, SOTOS SYNDROME 1, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, ADRENAL CORTICAL CARCINOMA, ADENOMAS, SALIVARY GLAND PLEOMORPHIC, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, TUMOR PREDISPOSITION SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, LYNCH SYNDROME I, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, THROMBOCYTOPENIA 5, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, PAPILLARY THYROID CARCINOMA, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

PCNA, GATA1, CHEK2, RET, PAX7, TSG101, TP53, MYC, SMAD4, CREBBP, AR, ETV6, GDNF, ATM, CDKN2A, BUB1B, GATA2, PPARG, ESR1, PLAG1, NSD1, IL6, BRCA1, BAP1, AKT1, SMARCA4, MSH2, TLR4, CCND1, FGFR2, MMP1, HOXB13, RUNX1, CDKN1B, IL1B, PHOX2B, NKX2-1, KAT5, LZTR1, SUFU, MEN1, EP300, FOXO1, PTEN, SMARCB1, MAX, CDKN1C, CDK4, IFNG, ERBB2, BDNF, NME1, STAT3, CASP8, TGFBR2, CTNNB1, RB1, PAX3

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, ATAXIA-TELANGIECTASIA, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, IMMUNODEFICIENCY 21, PANCREATIC CANCER/MELANOMA SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, SOTOS SYNDROME 1, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, ADENOMAS, SALIVARY GLAND PLEOMORPHIC, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, TUMOR PREDISPOSITION SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, LYNCH SYNDROME I, ADRENAL CORTICAL CARCINOMA, MULTIPLE ENDOCRINE NEOPLASIA 1, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, THROMBOCYTOPENIA 5, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, PAPILLARY THYROID CARCINOMA, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

GATA1, MEN1, SMARCA4, TP53, MYC, SMAD4, AR, ETV6, GDNF, ATM, CDKN2A, GATA2, PPARG, ESR1, PLAG1, NSD1, BRCA1, AKT1, CTNNB1, MSH2, TLR4, CCND1, HOXB13, RUNX1, PAX7, PHOX2B, NKX2-1, KAT5, LZTR1, SUFU, RET, EP300, FOXO1, PTEN, SMARCB1, MAX, CHEK2, RB1, BDNF, CREBBP, STAT3, TGFBR2, BAP1, ERBB2, PAX3

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, IMMUNODEFICIENCY 21, PANCREATIC CANCER/MELANOMA SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, LI-FRAUMENI SYNDROME, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULTIPLE ENDOCRINE NEOPLASIA IIB, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, PROTEUS SYNDROME, SOMATIC, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA

GATA1, CTNNB1, RUNX1, MYC, PAX3, CDKN2A, GATA2, PPARG, STAT3, BRCA1, AKT1, SMARCA4, CCND1, TP53, NKX2-1, CHEK2, RET, EP300, GDNF, RB1, CREBBP, ESR1

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, TUBEROUS SCLEROSIS 2, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, LI-FRAUMENI SYNDROME, BURKITT LYMPHOMA, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, MULIBREY NANISM, ATAXIA-TELANGIECTASIA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, PROTEUS SYNDROME, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, ADRENAL CORTICAL CARCINOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

ATM, FASLG, IL6, TP53, CASP8, SMAD4, MYC, TRIM37, FAS, AKT1, MYD88, IFNG

{SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, NEUROFIBROMATOSIS, TYPE 2, BANNAYAN-RILEY-RUVALCABA SYNDROME, RUBINSTEIN-TAYBI SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, 46XY SEX REVERSAL 6, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

CBL, NF2, MAP3K1, PARK2, PTEN, AURKA, CREBBP, EPHB2, CASP8, AXIN1, AKT1, DLC1, HRAS

ATAXIA-TELANGIECTASIA, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, OCCIPITAL HORN SYNDROME, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, ?N SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ANDROGEN INSENSITIVITY, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, ROTHMUND-THOMSON SYNDROME, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, LYNCH SYNDROME I, ADRENAL CORTICAL CARCINOMA, XERODERMA PIGMENTOSUM, GROUP B, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, NEUROFIBROMATOSIS, TYPE 1, XERODERMA PIGMENTOSUM, GROUP D, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, LI-FRAUMENI SYNDROME, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA

BRCA2, MSH6, MLH3, AURKA, MYC, TLR4, PTEN, ATR, AR, WRN, ATM, ERCC3, ATP7A, BLM, HAX1, KIF1B, RECQL4, CTNNB1, MSH2, PHB, ABCC11, BRIP1, RAD54B, RTEL1, PCNA, AXIN1, PMS2, SMARCA4, RAD51, TP53, POLE, CDK4, MLH1, ERCC2, NF1, ABCB11, NHP2, ESR1, XRCC3, PDGFRB, POLA1

PROSTATE CANCER 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, XERODERMA PIGMENTOSUM, GROUP F, {WILMS TUMOR SUSCEPTIBILITY-5}, IMMUNODEFICIENCY 21, PEUTZ-JEGHERS SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, NIJMEGEN BREAKAGE SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, DESMOID DISEASE, HEREDITARY, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, SOTOS SYNDROME 1, BROOKE-SPIEGLER SYNDROME, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, IMMUNODEFICIENCY, COMMON VARIABLE, 13, AGAMMAGLOBULINEMIA, X-LINKED 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUIJS-AALFS SYNDROME, RUBINSTEIN-TAYBI SYNDROME, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, PALMOPLANTAR HYPERKERATOSIS AND TRUE HERMAPHRODITISM, PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND SEX REVERSAL, BECKWITH-WIEDEMANN SYNDROME, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OLIGODONTIA-COLORECTAL CANCER SYNDROME, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, ROTHMUND-THOMSON SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, CURRARINO SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, LI-FRAUMENI SYNDROME, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, {BUDD-CHIARI SYNDROME}, SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME, NOONAN SYNDROME 4, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, IMMUNODEFICIENCY 14, LEIOMYOMATOSIS AND RENAL CELL CANCER, BANNAYAN-RILEY-RUVALCABA SYNDROME, PAGET DISEASE OF BONE 6, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, ADENOMAS, SALIVARY GLAND PLEOMORPHIC, SOMATIC, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, FAMILIAL ADENOMATOUS POLYPOSIS 3, XERODERMA PIGMENTOSUM, GROUP B, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, LYMPHOPROLIFERATIVE SYNDROME 1, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BLOOM SYNDROME, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, ANDROGEN INSENSITIVITY, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D2, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, TUMOR PREDISPOSITION SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, {THYROID CANCER, NONMEDULLARY, 4}, FANCONI ANEMIA, COMPLEMENTATION GROUP T, SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, THROMBOCYTOPENIA 5, XERODERMA PIGMENTOSUM, GROUP D, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, BRCA2, MSH6, MAD1L1, MYC, POT1, F5, GNAS, MYD88, BMPR1A, SMARCA4, MLH1, RBBP8, CYLD, PPARG, RECQL4, CTNNB1, BTK, SOS1, IKZF1, STK11, CDKN2A, WT1, IL1B, FH, MMP1, LIG4, NBN, POLE, CDC73, ERCC2, SNAI2, PDGFRB, CREBBP, MSH2, BAP1, PTEN, FANCD2, SMARCB1, PCNA, NF2, ERBB2, MLH3, IL1RN, KRAS, RUNX1, TRIM28, CASP8, LZTR1, NME1, WRN, ERCC3, HOXB13, BUB1B, IGF2R, GATA2, FGFR1, PLAG1, PIK3CD, NTHL1, SMARCE1, CCND1, MET, PAX7, NKX2-1, MEN1, EP300, FGFR3, RAD51, MAX, IFNG, RB1, ITK, STX11, STAT3, FOXE1, ACD, ACVR1B, GATA1, TGFBR1, SETBP1, VHL, TSG101, SUFU, RAD54L, SMAD4, ETV6, FOXO1, ERCC4, APC, UBE2T, ZFHX3, BRCA1, AKT1, RSPO1, KAT5, AIP, ZNF687, ASCL1, PARK2, AXIN2, MNX1, BRIP1, PHOX2B, TWIST1, TP53, POLD1, CDH1, MCM4, TINF2, CDKN1C, XRCC3, NF1, XRCC4, PAX3, TNNT2, AXIN1, KIT, TLR2, POLA1, DDX41, BARD1, AR, KLF6, AURKA, CHEK2, TLR4, GTF2H5, POU6F2, NTRK1, PTPN11, ATM, RNF6, MXI1, PALB2, DKC1, INSR, SPRTN, KARS, BLM, FGFR2, ODC1, IL6, CDKN1B, PHB, PMS2, RTEL1, BDNF, RAD54B, RET, LZTS1, HRAS, DCC, GDNF, FASLG, CDK4, RNASEL, NHP2, TERT, ATR, ESR1, TGFBR2, TRIM37, NSD1, PDGFB, DICER1

NEUROFIBROMATOSIS-NOONAN SYNDROME, XERODERMA PIGMENTOSUM, GROUP B, WERNER SYNDROME, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, ROTHMUND-THOMSON SYNDROME, LI-FRAUMENI SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, NEUROFIBROMATOSIS, TYPE 1, XERODERMA PIGMENTOSUM, GROUP D, ?N SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, ADRENAL CORTICAL CARCINOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

ERCC3, ERCC2, WRN, TP53, BRIP1, NF1, RAD54B, RTEL1, PCNA, BLM, MCM4, RAD51, RECQL4, POLA1, POLE

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, BECKWITH-WIEDEMANN SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, ANDROGEN INSENSITIVITY, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, SOTOS SYNDROME 1, ADRENAL CORTICAL CARCINOMA, SMALL CELL CANCER OF THE LUNG, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, BREAST-OVARIAN CANCER, FAMILIAL 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, TUMOR PREDISPOSITION SYNDROME, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}

LIG4, MYC, POT1, AR, NSD1, STAT3, BRCA1, TP53, TRIM28, PIK3CD, CCND1, CDKN1B, PCNA, SMARCA4, EP300, CDC73, RB1, LZTR1, CREBBP, ESR1, BAP1, PTEN

MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, BANNAYAN-RILEY-RUVALCABA SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC

ACVR1B, PTEN, TGFBR2, TGFBR1, BMPR1A

JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, ATAXIA-TELANGIECTASIA, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, GLIOMA SUSCEPTIBILITY 1, {BUDD-CHIARI SYNDROME}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, SMALL CELL CANCER OF THE LUNG, SOMATIC, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BECKWITH-WIEDEMANN SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, LEPRECHAUNISM, PANCREATIC CANCER/MELANOMA SYNDROME, PEUTZ-JEGHERS SYNDROME, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, {MELANOMA, CUTANEOUS MALIGNANT, 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, {MELANOMA, CUTANEOUS MALIGNANT, 2}, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CARNEY COMPLEX, TYPE 1, DESMOID DISEASE, HEREDITARY, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, TROPICAL CALCIFIC PANCREATITIS, {FIBROCALCULOUS PANCREATIC DIABETES, SUSCEPTIBILITY TO}, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, WERNER SYNDROME, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, IMMUNODEFICIENCY 14, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, LYMPHOPROLIFERATIVE SYNDROME 2, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, RUBINSTEIN-TAYBI SYNDROME, ADRENAL CORTICAL CARCINOMA, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, AGAMMAGLOBULINEMIA, X-LINKED 1, TUBEROUS SCLEROSIS 2, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, DIAMOND-BLACKFAN ANEMIA 1, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

FASLG, SERPINC1, NF2, GPC3, PPARG, SMARCA4, AURKA, MYC, POT1, SMAD4, F5, BARD1, WRN, AKT1, MYD88, FOXO1, ATM, SPINK1, MXI1, HAX1, WWOX, VHL, ESR1, INSR, ERBB2, PRKAR1A, IL6, PIK3CD, CDH1, CTNNB1, KAT5, CBL, FGFR1, STK11, BRCA1, CCND1, MET, RB1, CDKN1B, IL1B, TLR4, PCNA, CASP8, TGFBR1, EP300, PIK3CA, TP53, APC, SOS1, HRAS, DCC, TINF2, CDKN1C, CDK4, RPS19, CD27, PTEN, IL1RN, SERPINA1, CREBBP, CDKN2A, STAT3, BAX, BTK, ODC1, MMP1, PDGFRB, COL7A1

PROSTATE CANCER 1, {SCHWANNOMATOSIS-2, SUSCEPTIBILITY TO}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, XERODERMA PIGMENTOSUM, GROUP F, IMMUNODEFICIENCY 21, PEUTZ-JEGHERS SYNDROME, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, XERODERMA PIGMENTOSUM, GROUP D, {RHABDOID PREDISPOSITION SYNDROME 1}, RHABDOID TUMORS, SOMATIC, PARAGANGLIOMAS 5, NIJMEGEN BREAKAGE SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIB, DESMOID DISEASE, HEREDITARY, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, BROOKE-SPIEGLER SYNDROME, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT, CARCINOID TUMORS, INTESTINAL, AGAMMAGLOBULINEMIA, X-LINKED 1, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME}, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, {NEUROBLASTOMA, SUSCEPTIBILITY TO, 1}, NEUROBLASTOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1, {GLIOMA SUSCEPTIBILITY 9}, RUBINSTEIN-TAYBI SYNDROME, B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY, OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, IMMUNODEFICIENCY 24, BECKWITH-WIEDEMANN SYNDROME, LEPRECHAUNISM, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MULIBREY NANISM, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 4, DYSKERATOSIS CONGENITA, X-LINKED, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, OCCIPITAL HORN SYNDROME, MULTIPLE ENDOCRINE NEOPLASIA IIA, DENYS-DRASH SYNDROME, ROTHMUND-THOMSON SYNDROME, {PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1}, LYNCH SYNDROME I, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, CYLINDROMATOSIS, FAMILIAL, TUBEROUS SCLEROSIS 2, MULTIPLE ENDOCRINE NEOPLASIA 1, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1, LI-FRAUMENI SYNDROME, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, EMBERGER SYNDROME, PARAGANGLIOMAS 1, WITH OR WITHOUT DEAFNESS, NOONAN SYNDROME 4, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 10}, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, ATAXIA-TELANGIECTASIA, {MELANOMA, CUTANEOUS MALIGNANT, 3}, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, IMMUNODEFICIENCY 14, LEIOMYOMATOSIS AND RENAL CELL CANCER, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, ADRENAL CORTICAL CARCINOMA, IMMUNODEFICIENCY 8, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, ?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, FAMILIAL ADENOMATOUS POLYPOSIS 3, XERODERMA PIGMENTOSUM, GROUP B, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, LYMPHOPROLIFERATIVE SYNDROME 1, COWDEN SYNDROME 7, NEUROFIBROMATOSIS, TYPE 2, BREAST-OVARIAN CANCER, FAMILIAL 1, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, {MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO}, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, PITUITARY ADENOMA, PROLACTIN-SECRETING, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, TUBEROUS SCLEROSIS-1, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, ?N SYNDROME, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, CHOROID PLEXUS PAPILLOMA, MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, TYROSINEMIA, TYPE I, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BLOOM SYNDROME, FRASIER SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, PLEUROPULMONARY BLASTOMA, PANCREATIC CANCER/MELANOMA SYNDROME, 46XY SEX REVERSAL 6, ANDROGEN INSENSITIVITY, PARATHYROID ADENOMA WITH CYSTIC CHANGES, HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, PIEBALDISM, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D2, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, NEUROFIBROMATOSIS, TYPE 1, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CARNEY COMPLEX, TYPE 1, PAPILLARY THYROID CARCINOMA, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, {MESOTHELIOMA, SOMATIC}, MESOTHELIOMA, SOMATIC, TUMOR PREDISPOSITION SYNDROME, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, FANCONI ANEMIA, COMPLEMENTATION GROUP T, SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, NEUROCUTANEOUS MELANOSIS, SOMATIC, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, THROMBOCYTOPENIA 5, DIAMOND-BLACKFAN ANEMIA 1, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TSC2, BRCA2, MSH6, MAD1L1, MYC, POT1, FAS, GNAS, MYD88, BMPR1A, STK10, RBBP8, CYLD, PPARG, DKC1, PRKAR1A, IL6, CTPS1, BTK, STK11, CDKN2A, WT1, IL1B, FH, FGFR4, PIK3CA, NBN, POLE, PTPRJ, CDC73, RPS19, ERCC2, PDGFRB, CREBBP, MSH2, BAP1, PTEN, FANCD2, NF2, ERBB2, MLH3, FGFR3, LIG4, RUNX1, TRIM28, RB1CC1, DLC1, LZTR1, NME1, WRN, IDH1, IDH2, ERCC3, HOXB13, BUB1B, IGF2R, GATA2, MLH1, FGFR1, PIK3CD, NTHL1, CBL, SMARCE1, CCND1, MET, PAX7, NKX2-1, MEN1, EP300, RAD51, HIP1, KRAS, TNNT2, RB1, ITK, PCNA, STAT3, FAH, SEC23B, ACD, SEPT9, ACVR1B, GATA1, TGFBR1, VHL, CTNNB1, DDX41, CDKN3, RAD54L, SMAD4, SDHD, ETV6, FOXO1, TJP2, UBE2T, KIF1B, BRCA1, AKT1, SMARCA4, KAT5, AIP, ASCL1, CARD11, PARK2, TP53, BRIP1, PHOX2B, CHEK2, IFNG, POLD1, RECQL4, MCM4, CDKN1C, HAX1, XRCC3, NF1, XRCC4, ABCB11, BRAF, AXIN1, KIT, TLR2, POLA1, ABCC11, NRAS, AR, CORO1A, SMARCB1, AURKA, EPHB2, TLR4, PIK3R2, NTRK1, SDHA, PTPN11, ATM, PTPN12, RRAS2, ATP7A, BCL10, ERCC4, ESR1, MAP3K1, INSR, SOS1, KARS, BLM, FGFR2, TINF2, BAX, CDKN1B, PHB, PMS2, RTEL1, BDNF, RAD54B, RET, APC, HRAS, DCC, FASLG, CDK4, RNASEL, NHP2, TERT, ATR, TSC1, CDH1, CASP8, TGFBR2, TRIM37, MMP1, DICER1, PDGFB

FANCONI ANEMIA, COMPLEMENTATION GROUP D2, ?DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6, ?DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, ?N SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER

ACD, PCNA, RAD51, POLA1, FANCD2

OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, SCHOPF-SCHULZ-PASSARGE SYNDROME, GLIOMA SUSCEPTIBILITY 1, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, BECKWITH-WIEDEMANN SYNDROME, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BANNAYAN-RILEY-RUVALCABA SYNDROME, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR, EBD INVERSA, {EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, MODIFIER OF}, SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, MULTIPLE ENDOCRINE NEOPLASIA IIB, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, MULTIPLE ENDOCRINE NEOPLASIA IIA, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE MYELOMA, SUSCEPTIBILITY TO}, {MULTIPLE MYELOMA, RESISTANCE TO}, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ALAGILLE SYNDROME, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, CHOROID PLEXUS PAPILLOMA, TUBEROUS SCLEROSIS 2, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, ADRENAL CORTICAL CARCINOMA, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, RUBINSTEIN-TAYBI SYNDROME, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

TGFBR1, FGFR1, CTNNB1, TP53, MYC, SERPINA1, PTEN, GPC3, AKT1, NTRK1, TWIST1, BMPR1A, PDGFRB, GDNF, PPARG, ESR1, IL6, WNT10A, CDH1, PAX7, KAT5, FGFR4, SMARCE1, CCND1, RUNX1, IFNG, BDNF, PAX3, RET, EP300, FOXO1, SOS1, HRAS, CDKN1C, JAG1, ERBB2, FGFR3, PCNA, CREBBP, STAT3, PDGFB, MMP1, TGFBR2, ACVR1B

RETINOBLASTOMA, TRILATERAL, RETINOBLASTOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, {BREAST-OVARIAN CANCER, FAMILIAL, 2}, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, ?N SYNDROME, FANCONI ANEMIA, COMPLEMENTATION GROUP D1, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, WILMS TUMOR, SOMATIC, WILMS TUMOR, WILMS TUMOR, TYPE 1, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, SMALL CELL CANCER OF THE LUNG, SOMATIC, BREAST-OVARIAN CANCER, FAMILIAL 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, {GLIOBLASTOMA 3}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, RUBINSTEIN-TAYBI SYNDROME, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, CHOROID PLEXUS PAPILLOMA

CREBBP, BRCA2, TP53, VHL, ESR1, MYC, SMAD4, POLA1, SMARCA4, EP300, SMARCE1, RB1, KAT5

ATAXIA-TELANGIECTASIA, PULMONARY FIBROSIS, IDIOPATHIC, {PULMONARY FIBROSIS, IDIOPATHIC, SUSCEPTIBILITY TO}, OCCIPITAL HORN SYNDROME, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, ?N SYNDROME, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, BLOOM SYNDROME, MISMATCH REPAIR CANCER SYNDROME, {MELANOMA, CUTANEOUS MALIGNANT, 3}, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1, IMMUNODEFICIENCY 14, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, MUIR-TORRE SYNDROME, TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, NEUROFIBROMATOSIS-NOONAN SYNDROME, WERNER SYNDROME, ROTHMUND-THOMSON SYNDROME, LYNCH SYNDROME I, ?CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, {COLORECTAL CANCER, SUSCEPTIBILITY TO, 12}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, XERODERMA PIGMENTOSUM, GROUP B, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, NEUROFIBROMATOSIS, TYPE 1, XERODERMA PIGMENTOSUM, GROUP D, [AXILLARY ODOR, VARIATION IN], [EARWAX, WET/DRY], [COLOSTRUM SECRETION, VARIATION IN], COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5, LI-FRAUMENI SYNDROME, CHOROID PLEXUS PAPILLOMA

MSH6, CTNNB1, TP53, MYC, TLR4, ATR, WRN, ATM, ERCC3, ATP7A, BLM, HAX1, PIK3CD, RECQL4, SMARCA4, MSH2, PHB, ABCC11, BRIP1, RAD54B, RTEL1, PCNA, PMS2, RAD51, POLE, CDK4, MLH1, ERCC2, NF1, ABCB11, NHP2, ESR1, XRCC3, PDGFRB, POLA1

?CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE, B, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, EMPHYSEMA DUE TO AAT DEFICIENCY, HEMORRHAGIC DIATHESIS DUE TO \'ANTITHROMBIN\' PITTSBURGH, EMPHYSEMA-CIRRHOSIS, DUE TO AAT DEFICIENCY, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, PROTEUS SYNDROME, SOMATIC, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA

PCNA, IL1B, BAX, IL6, RAD51, CTNNB1, TP53, KARS, MYC, EP300, POT1, PTEN, SERPINA1, FOXO1, AKT1, ERBB2, HRAS

NEUROCUTANEOUS MELANOSIS, SOMATIC, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, BURKITT LYMPHOMA, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, LEPRECHAUNISM, IMMUNODEFICIENCY 8, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1

CBL, PDGFRB, NRAS, MYC, INSR, CORO1A

MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, ?ATAXIA-TELANGIECTASIA-LIKE DISORDER, LEPRECHAUNISM, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, PROTEUS SYNDROME, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER, ?RAS-ASSOCIATED AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TYPE IV, SOMATIC, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, ADRENAL CORTICAL CARCINOMA, TUBEROUS SCLEROSIS 2, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}

PIK3CD, KRAS, IFNG, TP53, INSR, BDNF, PCNA, TGFBR1, STAT3, AKT1, PIK3R2, ERBB2, PTPN11

CHOROID PLEXUS PAPILLOMA, GLIOMA SUSCEPTIBILITY 1, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1, MYELOPROLIFERATIVE DISORDER WITH EOSINOPHILIA, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, LEPRECHAUNISM, ANDROGEN INSENSITIVITY, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, ACROMEGALY, SOMATIC, PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, RHABDOMYOSARCOMA 2, ALVEOLAR, RHABDOMYOSARCOMA, ALVEOLAR, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, MEDULLARY THYROID CARCINOMA, FAMILIAL, MEDULLARY THYROID CARCINOMA, ADRENAL CORTICAL CARCINOMA, ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS, {KAPOSI SARCOMA, SUSCEPTIBILITY TO}, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, DIAMOND-BLACKFAN ANEMIA 1, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, SAETHRE-CHOTZEN SYNDROME, SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, TYLOSIS WITH ESOPHAGEAL CANCER, DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

VHL, FGFR4, POT1, PTEN, AR, GNAS, NTRK1, IGF2R, HAX1, FGFR1, ESR1, INSR, CDH1, KAT5, SOS1, FGFR2, IL6, TP53, RHBDF2, BDNF, MYC, TGFBR1, FOXO1, AKT1, HRAS, IL1B, RPS19, PDGFRB, FGFR3, STAT3, TINF2, TGFBR2, PDGFB

OVARIAN CARCINOMA, SOMATIC,; OVARIAN CANCER, SOMATIC,; ADENOCARCINOMA, OVARIAN, SOMATIC,; {OVARIAN CANCER, SOMATIC},; OVARIAN CARCINOMA, JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME, MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1, GLIOMA SUSCEPTIBILITY 1, POLYPOSIS, JUVENILE INTESTINAL, JUVENILE POLYPOSIS SYNDROME, INFANTILE FORM, XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, XERODERMA PIGMENTOSUM, GROUP F, COSTELLO SYNDROME, CONGENITAL MYOPATHY WITH EXCESS OF MUSCLE SPINDLES, NOONAN SYNDROME 4, BLOOM SYNDROME, PANCREATIC CANCER/MELANOMA SYNDROME, ANDROGEN INSENSITIVITY, {MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10}, PIEBALDISM, {MELANOMA, CUTANEOUS MALIGNANT, 2}, {VON HIPPEL-LINDAU SYNDROME, MODIFIER OF}, VON HIPPEL-LINDAU SYNDROME, MENINGIOMA, {MENINGIOMA}, MENINGIOMA, SIS-RELATED, {MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO}, MENINGIOMA, NF2-RELATED, SOMATIC, LI-FRAUMENI SYNDROME, IMMUNODEFICIENCY 14, {RHABDOID TUMOR PREDISPOSITION SYNDROME 2}, BANNAYAN-RILEY-RUVALCABA SYNDROME, SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME, SOMATIC MOSAIC, CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 4, DESMOID DISEASE, HEREDITARY, GERM CELL TUMORS,; TESTICULAR TUMOR, SOMATIC,; SPERMATOCYTIC SEMINOMA, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, IMMUNODEFICIENCY 8, LEUKEMIA, MEGAKARYOBLASTIC, WITH OR WITHOUT DOWN SYNDROME, SOMATIC, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, CENTRAL HYPOVENTILATION SYNDROME, CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL, WITH OR WITHOUT HIRSCHSPRUNG DISEASE, HADDAD SYNDROME, COWDEN SYNDROME 1, LHERMITTE-DUCLOS SYNDROME, DYSKERATOSIS CONGENITA, X-LINKED, {MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO}, NEUROFIBROMATOSIS, TYPE 2, MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, BURKITT LYMPHOMA, NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA, SCHWANNOMATOSIS, {SCHWANNOMATOSIS-1, SUSCEPTIBILITY TO}, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, ADRENAL CORTICAL CARCINOMA, ADENOMATOUS POLYPOSIS COLI, GARDNER SYNDROME, BRAIN TUMOR-POLYPOSIS SYNDROME 2, {PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO}, PHEOCHROMOCYTOMA, {PHEOCHROMOCYTOMA, MODIFIER OF}, {GASTRIC CANCER RISK AFTER H. PYLORI INFECTION}, GASTRIC CANCER, FAMILIAL DIFFUSE, WITH OR WITHOUT CLEFT LIP AND/OR PALATE, GASTRIC CANCER, SOMATIC, {GLIOMA SUSCEPTIBILITY 9}, {SPITZ NEVUS OR NEVUS SPILUS, SOMATIC}, MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC, NEUTROPENIA, SEVERE CONGENITAL 3, AUTOSOMAL RECESSIVE, ESOPHAGEAL CARCINOMA, SOMATIC ESOPHAGEAL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, SOMATIC, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SOMATIC, ESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, {PROSTATE CANCER AGGRESSIVENESS QTL},; {PROSTATE CANCER, SUSCEPTIBILITY TO, SOMATIC},; {PROSTATE CANCER, HEREDITARY, 5},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 3},; {PROSTATE CANCER, FAMILIAL, SUSCEPTIBILITY TO},; {PROSTATE CANCER, SUSCEPTIBILITY TO, 4},; PROSTATE CANCER, SOMATIC,; PROSTATE CANCER, HEREDITARY,; {PROSTATE CANCER},; {PROSTATE CANCER, SOMATIC},; {PROSTATE CANCER, PROGRESSION OF},; {PROSTATE CANCER, SUSCEPTIBILITY TO}, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, JUVENILE MYELOMONOCYTIC LEUKEMIA NOONAN SYNDROME 1, MELANOMA, MALIGNANT, SOMATIC, MALIGNANT MELANOMA, SOMATIC, PROTEUS SYNDROME, SOMATIC

GATA1, MAD1L1, NF2, PPARG, TSG101, MYC, SMAD4, PTEN, AR, PIK3R2, AKT1, PTPN11, ERCC4, TJP2, CORO1A, VHL, DKC1, PIK3CD, CDH1, SMARCA4, BLM, CBL, CDKN2A, TP53, PTPN12, BDNF, TGFBR1, PIK3CA, APC, SOS1, HRAS, DCC, HAX1, TNNT2, HIP1, POT1, STAT3, KIT, CTNNB1, ERBB2

LYMPHOPROLIFERATIVE SYNDROME 2, MEDULLOBLASTOMA, DESMOPLASTIC, {MEDULLOBLASTOMA}, MEDULLOBLASTOMA, COLORECTAL CANCER,; {COLORECTAL CANCER},; {COLONIC ADENOMA RECURRENCE, REDUCED RISK OF},; {COLORECTAL CANCER, SUSCEPTIBILITY TO},; {COLON CANCER, SUSCEPTIBILITY TO},; COLON CANCER, SOMATIC,; COLORECTAL CANCER, SOMATIC, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV, OVARIAN CARCINOMA, SOMATIC, OVARIAN CANCER, SOMATIC, ADENOCARCINOMA, OVARIAN, SOMATIC, {OVARIAN CANCER, SOMATIC}, OVARIAN CARCINOMA, LI-FRAUMENI SYNDROME, BURKITT LYMPHOMA, RUBINSTEIN-TAYBI SYNDROME, BREAST CANCER, SOMATIC, BREAST CANCER, EARLY-ONSET, {BREAST CANCER, PROTECTION AGAINST}, {BREAST CANCER, INVASIVE DUCTAL}, {BREAST CANCER, MALE, SUSCEPTIBILITY TO}, BREAST CANCER, {BREAST CANCER}, {BREAST CANCER, LOBULAR}, {?BREAST CANCER SUSCEPTIBILITY}, {BREAST CANCER, SUSCEPTIBILITY TO}, HEPATOCELLULAR CANCER, SOMATIC, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, SOMATIC, HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC, PROTEUS SYNDROME, SOMATIC, PANCREATIC CANCER, SOMATIC, PANCREATIC CANCER, SOMATIC PANCREATIC CANCER, PANCREATIC CARCINOMA, SOMATIC, CHOROID PLEXUS PAPILLOMA, AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, ADRENAL CORTICAL CARCINOMA, GLIOBLASTOMA, SOMATIC,; {GLIOMA, SUSCEPTIBILITY TO, SOMATIC},; {GLIOMA SUSCEPTIBILITY 1}